These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36496836)

  • 1. Plasma Amino Acids in Horses Suffering from Pituitary Pars Intermedia Dysfunction.
    Stoeckle SD; Timmermann D; Merle R; Gehlen H
    Animals (Basel); 2022 Nov; 12(23):. PubMed ID: 36496836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
    Copas VE; Durham AE
    Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
    Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
    Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
    Rendle DI; Litchfield E; Heller J; Hughes KJ
    Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
    Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
    BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
    McGowan TW; Pinchbeck GP; McGowan CM
    Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.
    Mc Gowan TW; Pinchbeck GP; Mc Gowan CM
    Equine Vet J; 2013 Jan; 45(1):66-73. PubMed ID: 22563728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.
    Miller AB; Murphy BA; Adams AA
    Domest Anim Endocrinol; 2022 Jan; 78():106651. PubMed ID: 34656964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
    Beech J; Boston R; Lindborg S
    J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction.
    Beech J; Boston RC; McFarlane D; Lindborg S
    J Am Vet Med Assoc; 2009 Sep; 235(6):715-22. PubMed ID: 19751169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses.
    Hu K; Stewart AJ; Yuen KY; Hinrichsen S; Dryburgh EL; Bertin FR
    J Vet Intern Med; 2020 May; 34(3):1350-1356. PubMed ID: 32255541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of pro-opiomelanocortin and encoded peptides, and their processing enzymes in equine pituitary pars intermedia dysfunction.
    Carmalt JL; Mortazavi S; McOnie RC; Allen AL; Unniappan S
    PLoS One; 2018; 13(1):e0190796. PubMed ID: 29309431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.
    McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE
    J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Case Series of Clinical Signs and Adrenocorticotrophin (ACTH) Concentrations in Seven Horses Transitioning to Pituitary Pars Intermedia Dysfunction (PPID).
    Kirkwood NC; Hughes KJ; Stewart AJ
    Vet Sci; 2022 Oct; 9(10):. PubMed ID: 36288186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Term Effects of Temperature and Thyrotropin-Releasing Hormone Stimulation on Adrenocorticotropin Stability in Horses.
    Hinrichsen SL; Yuen KY; Dryburgh EL; Bertin FR; Stewart AJ
    Animals (Basel); 2022 Jan; 12(3):. PubMed ID: 35158648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
    Rendle DI; Duz M; Beech J; Parkin T; Durham AE
    J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
    Donaldson MT; Jorgensen AJ; Beech J
    J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between insulin dysregulation and adrenocorticotropic hormone in aged horses and ponies with no clinical signs of pituitary pars intermedia dysfunction.
    Li FI; Spence RJ; de Laat MA; Harris PA; Sonntag J; Menzies-Gow NJ; Durham AE; Bailey SR; Sillence MN
    Equine Vet J; 2023 Nov; 55(6):1003-1011. PubMed ID: 36641787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
    McFarlane D; Banse H; Knych HK; Maxwell LK
    J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.